ArticleCell death discovery2022
Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer.
Article in Cell death discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- The clinical benefit of adding anlotinib to chemoradiothearpy in high-grade gliomas: a systematic review, meta-analysis, and specific analysis on glioblastoma.Clinical and experimental medicine · 2026Pooled it
- Low-dose radiotherapy as an immunomodulator in cancer: dose-specific mechanisms and hybrid high-dose/low-dose strategies.Biomarker research · 2026Review
- Review
- Spotlight on cGAS-STING: role in disease pathogenesis and therapeutic potential.Molecular biomedicine · 2026Review
- Boron neutron capture therapy combined with immunotherapy: insights from radiotherapy, BNCT-specific evidence, and future directions.Frontiers in immunology · 2026Review
- A rare pulmonary epithelioid angiosarcoma with ALK rearrangement: a case report and literature review.Frontiers in oncology · 2026Article
- Benmelstobart+anlotinib: an emerging therapeutic option in the targeted-immunotherapy era.Frontiers in oncology · 2026Review
- Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study.Frontiers in pharmacology · 2026Article
- Efficacy and safety of anlotinib maintenance therapy in limited-stage small cell lung cancer.Discover oncology · 2025Article
- Research progress of anti-angiogenic therapy combined with immunotherapy and radiotherapy for the treatment of brain metastases in non-small cell lung cancer (Review).Oncology letters · 2025Review
- Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of α-fetoprotein.Scientific reports · 2025Article
- The cGAS-STING pathway in cancer immunity: dual roles, therapeutic strategies, and clinical challenges.Essays in biochemistry · 2025Review
- Computational Cellular Mathematical Model Aids Understanding the cGAS-STING in NSCLC Pathogenicity.Bio-protocol · 2025Article
- Chemoradiotherapy with or Without Anlotinib for Postoperative Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma: A Real-World Observational Study.Drug design, development and therapy · 2025Observational
- [Aumolertinib combined with anlotinib inhibits proliferation of non-small cell lung cancer cells by down-regulating the PI3K/AKT pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma.Experimental hematology & oncology · 2024Article
- BIBR1532 combined with radiotherapy induces ferroptosis in NSCLC cells and activates cGAS-STING pathway to promote anti-tumor immunity.Journal of translational medicine · 2024Article
- Role of STING in the treatment of non-small cell lung cancer.Cell communication and signaling : CCS · 2024Review
- Neuroblastoma: an ongoing cold front for cancer immunotherapy.Journal for immunotherapy of cancer · 2023Review
- Using triple radio-immunotherapy to overcome cancer immunotherapy resistance.Cancer biology & medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Radiation resistance and unsatisfactory efficacy of radioimmunotherapy are important barriers to non-small cell lung cancer (NSCLC) treatment. The impacts of anlotinib on radiation and tumor immune microenvironment (TIME) in NSCLC remain to be resolved. Here, we find anlotinib enhances radiosensitivity, and further increases radiotherapy-stimulated CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.